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Introduction. 5-Aminolevulinic Acid (5-ALA) is a precursor of heme synthesis. Ametabolite, protoporphyrin IX (PpIX), selectively
accumulates in neoplastic tissue including glioblastoma. Presurgical administration of 5-ALA forms the basis of fluorescence-
guided resection (FGR) of glioblastoma (GBM) tumors. However, not all gliomas accumulate sufficient quantities of PpIX to
fluoresce, thus limiting the utility of FGR. We therefore developed an assay to determine cellular and pharmacological factors
that impact PpIX fluorescence in GBM. This assay takes advantage of a GBM cell line engineered to express yellow fluorescent
protein.Methods. The human GBM cell line U87MG was transfected with a YFP expression vector. After treatment with a series of
5-ALA doses, both PpIX and YFP fluorescence were measured. The ratio of PpIX to YFP fluorescence was calculated. Results. YFP
fluorescence permitted the quantification of cell numbers and did not interferewith 5-ALAmetabolism.ThePpIX/YFPfluorescence
ratio provided accurate relative PpIX levels, allowing for the assessment of PpIX accumulation in tissue. Conclusion. Constitutive
YFP expression strongly correlates with cell number and permits PpIX quantification. Absolute PpIX fluorescence alone does not
provide information regarding PpIX accumulation within the cells. Our research indicates that our PpIX/YFP ratio assay may be a
promising model for in vitro 5-ALA testing and its interactions with other compounds during FGR surgery.
1. Introduction
Glioblastoma multiforme (GBM) is the most common and
aggressive primary malignant brain tumor. With the current
standard of care, recurrence is inevitable and less than 5% of
GBMpatients will survive five years after diagnosis [1]. Subto-
tal surgical resection may contribute to recurrence as tumor
initiating cells are left in place. A valuable tool to achieve
gross total resection and thereby increase progression-free
survival is the use of 5-Aminolevulinic Acid (5-ALA) for
fluorescence-guided resection (FGR) [2]. 5-ALA is a substrate
of the heme biosynthesis pathway and is the source of carbon
for porphyrin synthesis [3]. Malignant gliomas metabolize 5-
ALA and accumulate the fluorescent compound, protopor-
phyrin IX (PpIX) [4]. The presence of PpIX fluorescence
within the tumor bed allows for discrimination between
neoplastic and nonneoplastic cells [4]. Yet, not all brain
tumors accumulate sufficient quantities of PpIX to make the
use of 5-ALA advantageous during surgery [5, 6], and it is
not fully understood how 5-ALA might affect other physi-
ological processes. At this time, it is unknown if prescribed
medications of tumor patients or if drugs given to patients
just prior to/during surgery interfere with 5-ALA synthesis
and/or PpIX accumulation. It is difficult, however, to test
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for the effects of these potential drug interactions during
in vitro analyses, because fluorescence of PpIX is merely
an indication of presence/absence of accumulation. PpIX
fluorescence detection alone does not provide understanding
about the number of metabolically active cells in an assay.
This lack of information coupled with the great potential of
5-ALA in FGR suggested that a quantitative analysis of the
metabolism of 5-ALA to fluorescent PpIX in tumors cells
would improve the methodologies used to detect neoplasms
during surgery. To accomplish this, we developed an in vitro
assay using a YFP-tagged glioblastoma cell line. This cell line
was then used to measure the rate of 5-ALA incorporation
and conversion to protoporphyrin IX.
2. Methods
2.1. Cell Lines. U87MG cells (ATCC, Manassas, VA, USA)
were cultured in phenol red-free Eagle’s minimum essential
medium (EMEM) with L-glutamine (Lonza, Portsmouth,
NH, USA) and 10% fetal bovine serum (PAA, Westborough,
MA, USA) at 37∘C and 5% CO
2
. U87MG cells were stably
transfected with the YFP expression vector (pEYFP-C1) to
create U87-YFP cells using the Neon transfection system
(Invitrogen, Life Technologies, Carlsbad, CA, USA) fol-
lowed by selection with G418 antibiotic (Gold Biotechnology,
St. Louis, MO, USA). U87MG transfection with YFP was
conducted as follows: U87MG cells were harvested using
Trypsin-Versene (Lonza, Portsmouth, NH, USA), counted,
and resuspended in Resuspension Buffer R (Neon transfec-
tion system, Invitrogen, Life Technologies, Carlsbad, CA,
USA) to a cell concentration of 5 × 106 cells/mL. A
cell+plasmid solution (9.5 uL resuspended cells and 0.5 uL
of the pEYFP-plasmid at a concentration of 1.7 ug/mL) was
prepared and 10 uLwas aspirated into aNeon reaction tip.The
Neon reaction tip was inserted into a Neon transfection tube
filled with approximately 3mL of Electrolytic Buffer (Neon
transfection system, Invitrogen, Life Technologies, Carlsbad,
CA, USA). Transfection was performed using a 1,300 pulse
voltage with a 30ms pulse width, as a single pulse. The 10
uL of transfected U87s was then pipetted into a prewarmed
EMEM + 10% FBS media solution lacking antibiotics in a
96-well plate. Cells were allowed to settle and incubate for
24 hours, and then the EMEM + 10% FBS solution was
replaced with media containing 0.8mg/mL G418 antibiotic.
After approximately two weeks, all of the remaining cells
expressed YFP. Amaintenance level of G418 (0.2mg/mL) was
then used to maintain selection pressure for YFP expressing
U87s. As cells became confluent they were transferred to 24-
well plates, then 6-well plates, and then finally T25 culture
flasks.
2.2. 5-Aminolevulinic Acid Treatment. 5-ALA (ACROS,
Thermo Fisher Scientific, Pittsburg, PA, USA) was dissolved
in phosphate buffered saline (Gibco, Life Technologies,
Grand Island, NY, USA), titrated to a pH of 3, and stored at
a concentration of 200mM at −20∘C. Cells were plated in
black-bottom microtiter plates (Greiner Bio-One, Monroe,
NC, USA) at a density of 5,000 cells per well. Cells were
treated with 5-ALA solutions at 50.0, 25.0, 12.5, 6.25, 3.13,
1.56 0.78, 0.39, 0.20, and 0.10mM. Dimethyl sulfoxide
(DMSO) (Amresco, Solon, OH, USA) was added to the
treatment to increase permeability of 5-ALA into the cells.
Pilot studies determined that 0.5% v/v DMSO maximized
5-ALA uptake and minimized cytotoxicity. A 2% v/v of
0.1mM ethylenediaminetetraacetic acid (EDTA) (Thermo
Fisher Scientific, Pittsburg, PA, USA) was also added to
reduce the availability of iron. Insulin (Sigma-Aldrich, St.
Louis, MO, USA) was added at a concentration of 30 𝜇g/mL
to the treatment media.
2.3. Fluorescence Measurement. PpIX and YFP fluorescence
weremeasured using aModulusMicroplate Reader (Promega
BioSystems, Sunnyvale, CA, USA), with a standard 525 nm
excitation/580–640 nm emission filter to detect YFP fluo-
rescence and a custom-made 405 nm excitation/580–640 nm
emission filter (Promega Corporation, Madison, WI, USA)
to detect PpIX fluorescence. To investigate the relationship
between YFP and cell number, U87-YFP cells were counted
and a standard curve was prepared by plating the cell
suspension in a series dilution. To investigate relative PpIX
fluorescence, baseline fluorescence values were determined at
the time of treatment (hour 0) and recorded at 8, 16, 24, 32,
40, 48, 56, 64, and 72 hours after treatment. PpIX and YFP
fluorescence were measured in the same plate in sequential
fashion. Relative PpIX fluorescence values (PpIX fluorescent
value per cell) were calculated by taking the ratio of the mean
PpIX relative light units (RLU) and YFP RLU (PpIX/YFP)
from each treatment well.
2.4. Statistical Analysis. A Pearson correlation coefficient
was calculated to determine a relationship between cell
number and YFP fluorescence. For PpIX florescence, indi-
vidual wells from each assay were analyzed as individual
values. A repeated measures analysis of variance (ANOVA)
was used to analyze the differences between 5-ALA treat-
ment concentrations and time points over 72 hours (SPSS,
Version 18, IBM, Armonk, NY, USA). Post hoc least sig-
nificant difference (LSD) analyses were used to deter-
mine statistical difference between concentrations and time
points. All values are expressed as a mean ± standard
error, and significant differences were determined at the
0.05 level.
3. Results
3.1. Relationship betweenYFP andCell Number. Todetermine
if yellow fluorescence emission at 580–640 nm would be a
reliable mechanism to determine cell number in a well, a
standard curve of U87-YFP cells was prepared. A Pearson
correlation coefficient was calculated to demonstrate the
relationship between YFP fluorescence and number of cells
in an assay plate well. A strong positive correlation was found
(𝑟 = 0.801 ± 0.053, 𝑃 < 0.01), indicating a significant linear
relationship between YFPRLU and the number of cells plated
into a microplate well.
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Figure 1: Confocal images of PpIX fluorescence (a), YFP fluorescence (b), and the overlay (c) of both for U87-YFP cells treated with 0.4mM
5-ALA for 2 hours.
3.2. Relative PpIX Fluorescence. After confirming YFP fluo-
rescence and 5-ALA metabolism (PpIX fluorescence) using
a confocal microscope (Figure 1), a microplate reader was
used to record YFP and PpIX fluorescence and determine
relative porphyrin synthesis by cells. PpIX fluorescence was
compared between the eleven 5-ALA concentrations (0.0,
0.10, 0.20, 0.39, 0.78, 1.56, 3.13 6.25, 12.5, 25.0, and 50.0mM)
and the ten different time points (0, 8, 16, 24, 32, 40, 48,
56, 64, and 72 hours) using a two-way repeated measures
ANOVA. When analyzing PpIX fluorescence alone, there
was a significant effect found for 5-ALA concentrations
(𝐹(10, 40) = 21.19, 𝑃 < 0.01), time (𝐹(9, 36) = 19.20, 𝑃 <
0.01), and the interaction of 5-ALA concentration and time
(𝐹(90, 360) = 12.54, 𝑃 < 0.01). Post hoc analyses revealed
the differences between concentrations (Figure 2) and time
points (Figure 3).
YFP fluorescence was also compared between each 5-
ALA concentration and time point. An effect was found
for YFP fluorescence for 5-ALA concentration (𝐹(10, 40) =
27.68, 𝑃 < 0.01), time (𝐹(9, 36) = 14.62, 𝑃 < 0.01) and their
interaction (𝐹(90, 360) = 8.41, 𝑃 < 0.01). For differences
between concentrations, see Figure 2, and for time points, see
Figure 3.
Further, the ratio of PpIX fluorescence to YFP fluores-
cence was compared to analyze a relative amount of PpIX
production within cells. For PpIX/YFP, there was an effect
found for 5-ALA concentration (𝐹(10, 40) = 18.35,𝑃 < 0.01),
time (𝐹(9, 36) = 5.87, 𝑃 < 0.01), and their interaction
(𝐹(90, 360) = 9.67, 𝑃 < 0.01). For differences between
concentrations, see Figure 2, and for time points, see Figure 3.
4. Discussion
There are several novel findings in this study: (1) constitutive
YFP fluorescence strongly correlates with cell number, (2)
in vitro PpIX fluorescence increases over time reflecting
increases in cell number, (3) utilizing constitutive YFP
expression in cells allows for attainable PpIX quantification in
vitro, and (4) 5-ALA treatments ≥ 25mM generated highest
amounts of PpIX/cell while decreasing the number of viable
cells. The utilization of YFP allowed for the detection of
changes in cell numbers without using traditional techniques
which typically damage or kill the cells—now longitudinal
designs are feasible with the same assay plate. Our lab
previously determined that YFP does not interfere with 5-
ALA metabolism and little to no cross-talk is detectible
when exciting these compounds. Thus, by making use of the
PpIX/YFP fluorescence ratio, relative PpIX levels per cell are
more accurately estimated and allow for the assessment of
PpIX accumulation or lack thereof.
Because YFP was demonstrated to be a reliable indicator
of cell number, a YFP expressing cell line provides a new
model for quantifying PpIX accumulation in vitro. A method
to quantify PpIX accumulation would allow researchers to
measure of the amount of PpIX per cell. Without this
quantification, PpIX fluorescence is merely an indication of
absence or presence. During a time course study, for example,
the number of cells in a well of an assay plate changes
(increases due to cell division or decreases due to cell death).
If PpIX fluorescence is recorded without accounting for the
change in cell number, there is no way to determine if PpIX is
accumulatingwithin these cells. Our data suggests that higher
concentrations of 5-ALA (Figure 2) may have a toxic effect in
cells, yet great PpIX accumulation within living cells of the
assay.These toxic effects may warrant future investigations of
5-ALA administration as a targeted therapeutic agent.
While the 5-ALA FGR method is viewed as a more
efficient means for tumor resection, there are limitations.
It is not fully understood how 5-ALA interacts with other
physiological processes and other pharmacological agents
when given systemically. 5-ALA use has been questioned
because PpIX fluorescence is weak or even absent in some
patients. This low PpIX fluorescence is possibly due to
interactions of 5-ALA with drugs and/or other compounds
circulating within tumor patients at the time of FGR surgery.
Low PpIX fluorescence may also be due to the lack of
individualized (patient by patient) standards regarding the
presurgical administration of 5-ALA to ensure peak PpIX
fluorescence. Currently, 20mg/kg of 5-ALA per body weight
is administered about 3 hours prior to surgery [7]. To our
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Figure 2: YFP and PpIX fluorescence and ANOVA main effects for each of the 5-ALA concentrations/treatments. Absolute fluorescence of
PpIX (a) displays a natural bell curve for the wide range of 5-ALA treatments. YFP fluorescence (b) was not altered except for the 5-ALA
treatment levels ≥12.5mM, suggesting that elevated 5-ALA concentrations may inhibit cell growth. The bottom figure (c) represents relative
PpIX accumulation (PpIX/YFP) and demonstrates that higher levels of 5-ALA allow for more PpIX production in living cells.
knowledge, alternative dosing strategies have not been tested
for efficacy. The PpIX/YFP method may allow for dosage
focused studies to be conducted.
Our data indicates that new studies designed to monitor
PpIXfluorescence over time should address cell growth/death
during the testing process—PpIX fluorescence in vitro is
dependent on the number of viable cells (Figure 3). Without
understanding about the number of metabolically active cells
in an assay, the fluorescence of PpIX is merely an indication
of presence or absence. Here, PpIX fluoresce values increased
over time (Figure 3(a)); however, YFP fluorescence values
also increased over time (Figure 3(b)). Further, when com-
paring relative PpIX fluorescence (Figure 3(c)), the amount
of PpIX per cell did not change. This knowledge allows
researchers to now investigate novel approaches to optimize
fluorescence. Optimizing PpIX fluorescence may improve
surgical outcomes and significantly increase the number of
brain tumors that accumulate sufficient quantity of PpIX for
FGR.
5. Conclusion
In summary, we showed that constitutive YFP expression
strongly correlates with cell number and can be used to
normalize PpIX fluorescence in vitro. We also showed that
recording PpIX fluorescence alone does not provide infor-
mation regarding accumulation of PpIX within cells, and we
discovered that high levels of 5-ALA treatment reduce cell
numbers during the time course warranting future investi-
gations of 5-ALA administration as a therapeutic agent. Our
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Figure 3: This figure displays YFP and PpIX fluorescence and ANOVA main effects for various points during a time course. Absolute
fluorescence of PpIX (a) displays an increase in fluorescence over time, suggesting that cells may need more time to metabolize 5-ALA
and accumulate PpIX. YFP fluorescence (b) was also increased over time, being indicative of cell growth over time. The bottom figure (c)
represents relative PpIX accumulation (PpIX/YFP). The ratio demonstrates that PpIX is dependent upon the number of cells available to
metabolize the 5-ALA and shows the importance of quantifying PpIX fluorescence.
PpIX/YFP ratio method is a feasible approach for in vitro
5-ALA analysis and may provide a new model for testing
interactions of 5-ALA with other compounds circulating
within tumor patients at the time of FGR surgery. These
interactions may determine why some tumors fluoresce and
others do not.
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